目的 評價康艾注射液輔助化學療法（化療）對直腸癌術后臨床療效、生活質量及其不良反應的影響。 方法 2010年4月－2011年2月收治的50例直腸癌術后化療患者，隨機分為試驗組與對照組，每組25例。兩組均采用FOLFOX方案化療，在化療同時，試驗組予靜脈滴注康艾注射液輔助治療。連續治療6個周期，比較兩組臨床療效、生活質量及其不良反應情況。 結果 試驗組治療有效率為84%，對照組為88%，差異無統計學意義（P＞0.05）；兩組生活質量改善率差異無統計學意義（P＞0.05）；試驗組胃腸道反應、白細胞計數下降發生率低于對照組，差異有統計學意義（P＜0.05）。 結論 康艾注射液用于直腸癌術后的輔助化療可降低化療的不良反應。
Background Tongxinluo capsule is a new drug for cardio- cerebral vascular diseases on the national essential drug list of China, and the second-class award of National Science and Technology Development of China, 2001. Objective This review aims to assess the effect (harms and benefits) of Tongxinluo capsule for unstable angina. Search strategy electronic searchs The Cochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register, published in the latest issue of the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese Cochrane Centre Controlled Trials Register, Current Controlled Trials (www. controlled-trials. com), The National Research Register Handsearchs We will search 83 journals of Chinese traditional medicine. Inclusion riteria We will include randomised controlled trials of Tonxinluo capsule versus placebo or other current phamarcotherapy or other Chinese medicinal herbs in the participants with unstable angina pectoris. Studies will report mortality (sudden death from acute myocardial infarction), severity of angina pectoris, frequency of acute attack angina, ECG improvement, rate of dosage reducing or taking frequency of nitroglycerine and symptom improvement, etc. Data analysis Data will be included in a meta-analysis if they are available, of sufficient quality and sufficiently similar.